Protease Inhibitors as Antiviral Agents

SUMMARY Currently, there are a number of approved antiviral agents for use in the treatment of viral infections. However, many instances exist in which the use of a second antiviral agent would be beneficial because it would allow the option of either an alternative or a combination therapeutic approach. Accordingly, virus-encoded proteases have emerged as new targets for antiviral intervention. Molecular studies have indicated that viral proteases play a critical role in the life cycle of many viruses by effecting the cleavage of high-molecular-weight viral polyprotein precursors to yield functional products or by catalyzing the processing of the structural proteins necessary for assembly and morphogenesis of virus particles. This review summarizes some of the important general features of virus-encoded proteases and highlights new advances and/or specific challenges that are associated with the research and development of viral protease inhibitors. Specifically, the viral proteases encoded by the herpesvirus, retrovirus, hepatitis C virus, and human rhinovirus families are discussed.

[1]  M. Murcko,et al.  Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide , 1996, Cell.

[2]  D. Ho,et al.  A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. , 1995, The New England journal of medicine.

[3]  K. Duffin,et al.  Activity of two-chain recombinant human cytomegalovirus protease. , 1994, The Journal of biological chemistry.

[4]  J. Barrish,et al.  Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease , 1995, Antimicrobial agents and chemotherapy.

[5]  B. Heinz,et al.  Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease , 1995 .

[6]  P. Volberding,et al.  HIV-1 protease inhibitors , 1992 .

[7]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[8]  R. De Francesco,et al.  NS3 is a serine protease required for processing of hepatitis C virus polyprotein , 1993, Journal of virology.

[9]  C. Rice,et al.  A second hepatitis C virus-encoded proteinase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Matthews,et al.  Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. , 1998, Journal of medicinal chemistry.

[11]  W. Newcomb,et al.  The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth , 1994, Journal of virology.

[12]  T. Merigan,et al.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.

[13]  H. B. Schock,et al.  Three-dimensional Structure of a Mutant HIV-1 Protease Displaying Cross-resistance to All Protease Inhibitors in Clinical Trials (*) , 1995, The Journal of Biological Chemistry.

[14]  C L Verlinde,et al.  Structure-based drug design: progress, results and challenges. , 1994, Structure.

[15]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[16]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[17]  M. Rossmann,et al.  Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. , 1992, Annual review of microbiology.

[18]  M. Otto,et al.  HIV protease inhibitors. , 1995, AIDS.

[19]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[20]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[21]  M. Yanagi,et al.  Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Andreoni,et al.  Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. , 1996, Antiviral research.

[23]  P. Tebas,et al.  Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. , 1999, AIDS.

[24]  Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. , 1996, Journal of medicinal chemistry.

[25]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[26]  M. Houghton,et al.  Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses , 1993, Journal of Virology.

[27]  David A. Matthews,et al.  Structure of the Human Cytomegalovirus Protease Catalytic Domain Reveals a Novel Serine Protease Fold and Catalytic Triad , 1996, Cell.

[28]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[29]  L. Sun,et al.  Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation. , 1996, Biochemistry.

[30]  D. Back,et al.  Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV‐infected patients , 1997, AIDS.

[31]  D. Ho,et al.  A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. , 1998, The Journal of infectious diseases.

[32]  H. Parge,et al.  The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site , 1996, Cell.

[33]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Urbani,et al.  Activity of purified hepatitis C virus protease NS3 on peptide substrates , 1996, Journal of virology.

[35]  D. Pevear,et al.  Antipicornavirus Drugs: Current Status , 1997 .

[36]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[37]  L. Pacini,et al.  Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus , 1997, Journal of virology.

[38]  A. D. Rodrigues,et al.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.

[39]  Andrew Carr,et al.  HIV protease inhibitors , 1996, AIDS.

[40]  T. Merigan,et al.  A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[41]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[42]  K. Wager-Smith,et al.  The Effect of Internal Autocleavage on Kinetic Properties of the Human Cytomegalovirus Protease Catalytic Domain (*) , 1995, The Journal of Biological Chemistry.

[43]  Y. Gluzman,et al.  Expression and analysis of the human cytomegalovirus UL80-encoded protease: identification of autoproteolytic sites , 1993, Journal of virology.

[44]  B. Dunn,et al.  Viral proteinases: weakness in strength. , 1990, Biochimica et biophysica acta.

[45]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[46]  A. Weiner,et al.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.

[47]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[48]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[49]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[50]  R. Bartenschlager,et al.  Kinetic and structural analyses of hepatitis C virus polyprotein processing , 1994, Journal of virology.

[51]  M. Murcko,et al.  Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication , 1997, Journal of virology.

[52]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[53]  K. von der Helm.  Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. , 1996, Biological chemistry.

[54]  J. Kappes,et al.  A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. , 1993, The New England journal of medicine.

[55]  J L Meek,et al.  Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. , 1996, Chemistry & biology.

[56]  E. Wimmer,et al.  Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity. , 1996, Virology.

[57]  E. Wimmer,et al.  Viral proteinases. , 1988, Annual review of biochemistry.

[58]  D. Vanderpool,et al.  Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. , 1996, Biochemistry.

[59]  I B Duncan,et al.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.

[60]  R. Bartenschlager,et al.  Determinants of substrate specificity in the NS3 serine proteinase of the hepatitis C virus. , 1997, Virology.

[61]  J. Culp,et al.  Unique fold and active site in cytomegalovirus protease , 1996, Nature.

[62]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[63]  C. Rice,et al.  Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites , 1993, Journal of virology.

[64]  M. Rizzetto,et al.  The long‐term efficacy of interferon alfa in chronic hepatitis C patients: A critical review , 1995, Journal of gastroenterology and hepatology.

[65]  J. Mestan,et al.  In Vitro Effect of α1-Acid Glycoprotein on the Anti—Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease Inhibitors , 1997 .

[66]  D Norbeck,et al.  Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor , 1994, Journal of virology.

[67]  D. Hamre,et al.  Activity of p-Aminobenzaldehyde, 3-Thiosemicarbazone on Vaccinia Virus in the Chick Embryo and in the Mouse , 1950 .

[68]  T. Meek.  Inhibitors of HIV-1 protease. , 1992, Journal of enzyme inhibition.

[69]  D. Kuritzkes,et al.  Human immunodeficiency virus type 1 protease inhibitors. , 1997, Archives of internal medicine.

[70]  B. Condon,et al.  Single-chain Recombinant Human Cytomegalovirus Protease , 1995, The Journal of Biological Chemistry.

[71]  J. Groves,et al.  Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. , 1996, Biochemistry.

[72]  B. Semler,et al.  Picornavirus protein processing--enzymes, substrates, and genetic regulation. , 1990, Current topics in microbiology and immunology.

[73]  D. J. Bauer.  Antiviral chemotherapy. , 1966, The Scientific basis of medicine annual reviews.

[74]  A. Patick,et al.  Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro , 1997, Antimicrobial agents and chemotherapy.

[75]  J. A. Martin,et al.  Recent advances in the design of HIV proteinase inhibitors. , 1992, Antiviral research.

[76]  K. Shimotohno,et al.  Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. , 1997, Biochemical and biophysical research communications.

[77]  B. Semler,et al.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. , 1993, Microbiological reviews.

[78]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[79]  P. Bonneau,et al.  A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease , 1996, Nature.

[80]  R. Murphy.  Novel approaches to three drug antiretroviral therapy for HIV infection in 1997 , 1997 .

[81]  E. De Clercq,et al.  Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538) , 1996, AIDS.

[82]  R. Francesco,et al.  Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins , 1994, Journal of virology.

[83]  M. Ott,et al.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.

[84]  S. Morris-Jones,et al.  Antiretroviral therapies in HIV-1 infection. , 1997, Expert opinion on investigational drugs.

[85]  M. Koffler.  Epidemiology of hepatitis. , 1965, Lancet.

[86]  R. Kurumbail,et al.  Three-dimensional structure of human cytomegalovirus protease , 1996, Nature.

[87]  Marc Allaire,et al.  Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases , 1994, Nature.

[88]  R. Francesco,et al.  Identification and properties of the RNA‐dependent RNA polymerase of hepatitis C virus. , 1996, The EMBO journal.

[89]  C. Rice,et al.  The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[90]  A. Kaplan,et al.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles , 1993, Journal of virology.

[91]  M. Houghton,et al.  The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. , 1993, Biochemical and biophysical research communications.

[92]  The 45-kilodalton protein of cytomegalovirus (Colburn) B-capsids is an amino-terminal extension form of the assembly protein , 1991, Journal of virology.

[93]  M. Alter,et al.  Epidemiology of Hepatitis C in the West , 1995, Seminars in liver disease.

[94]  Luis Carrasco.  Picornavirus inhibitors , 1994, Pharmacology & Therapeutics.

[95]  Y. Sung,et al.  Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity. , 1997, Journal of virological methods.

[96]  Giorgio,et al.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[97]  A. Cross,et al.  Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced Patients , 1997, Annals of Internal Medicine.

[98]  D. Richman,et al.  A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A , 1997, Antimicrobial agents and chemotherapy.

[99]  D. Ho,et al.  Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor , 1997, Antimicrobial agents and chemotherapy.

[100]  R. Bartenschlager,et al.  Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions , 1993, Journal of virology.

[101]  B. Heinz,et al.  Simple in vitro translation assay to analyze inhibitors of rhinovirus proteases , 1996, Antimicrobial agents and chemotherapy.

[102]  C. Rice,et al.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. , 1997, Science.

[103]  J. Barrish,et al.  Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor , 1995, Journal of virology.

[104]  P. Lam,et al.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor , 1993, Antimicrobial Agents and Chemotherapy.

[105]  W. Gibson,et al.  A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[106]  J. Weber,et al.  Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. , 1997, The Journal of antimicrobial chemotherapy.

[107]  Bradley Efron,et al.  The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients , 1996, Annals of Internal Medicine.

[108]  D. Ho,et al.  Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.

[109]  R. Myers,et al.  In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease , 1995, Journal of virology.

[110]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[111]  B. Dunn,et al.  A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. , 1995, Analytical biochemistry.

[112]  W Gibson,et al.  Structure and assembly of the virion. , 1996, Intervirology.

[113]  J. Erickson,et al.  Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.

[114]  P. Urvil,et al.  Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. , 1997, European journal of biochemistry.

[115]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[116]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[117]  B. Dasmahapatra,et al.  Structure of Sch 68631: A new hepatitis C virus proteinase inhibitor from Streptomyces sp. , 1996 .

[118]  W. Windsor,et al.  Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides , 1997, Journal of virology.

[119]  J. Kahn,et al.  HIV-1 protease inhibitors. A review for clinicians. , 1997 .

[120]  R. Whitley,et al.  New therapeutic approaches to the alphaherpesvirus infections. , 1997, The Journal of antimicrobial chemotherapy.

[121]  D. J. Bauer.  The antiviral and synergic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. , 1955, British journal of experimental pathology.

[122]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[123]  V. Blinov,et al.  Poliovirus‐encoded proteinase 3C: a possible evolutionary link between cellular serine and cysteine proteinase families , 1986, FEBS letters.

[124]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[125]  A. Breckenridge,et al.  Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients , 1997, AIDS.

[126]  N. Kato,et al.  Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus , 1993, Journal of virology.

[127]  R J Fletterick,et al.  Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[128]  D. Matthews,et al.  Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein , 1994, Cell.

[129]  R. Cortese,et al.  Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires , 1997, Journal of virology.

[130]  H. Hsiung,et al.  Human cytomegalovirus maturational proteinase: expression in Escherichia coli, purification, and enzymatic characterization by using peptide substrate mimics of natural cleavage sites , 1994, Journal of virology.

[131]  G. Migliaccio,et al.  Biosynthesis and biochemical properties of the hepatitis C virus core protein , 1994, Journal of virology.

[132]  D. Matthews,et al.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. , 1998, Journal of medicinal chemistry.